Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Keveyis for the Treatment of Primary Hyperkalemic and Hypokalemic Periodic Paralysis

Drug Name (Brand / Generic)

Keveyis (dichlorphenamide)

Developed by

Taro Pharmaceutical Industries

Therapy Class

Carbonic anhydrase inhibitor

Current Indication

Primary hyperkalemic and hypokalemic periodic paralysis

Market Sector

CNS

Development Status

Approved in the US
Expand

Go Top